LearnGlossaryMarketStocksSuperinvestorsSign in

XENE

Xenon Pharmaceuticals Inc.

Healthcare · $3.6B market cap

Verdict

We can't put a fair value on XENE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth13.5% a year✓
Sales growth-0.2% a year✗
Free cash flow growth—?
Return on invested capital-32.8%✗

Follow XENE

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Svoronos Dawn

director · 2026-09-01

Option exercise

$42K

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works